MX2024002838A - Metodos para tratar trastornos usando inhibidores de csf1r. - Google Patents
Metodos para tratar trastornos usando inhibidores de csf1r.Info
- Publication number
- MX2024002838A MX2024002838A MX2024002838A MX2024002838A MX2024002838A MX 2024002838 A MX2024002838 A MX 2024002838A MX 2024002838 A MX2024002838 A MX 2024002838A MX 2024002838 A MX2024002838 A MX 2024002838A MX 2024002838 A MX2024002838 A MX 2024002838A
- Authority
- MX
- Mexico
- Prior art keywords
- treating cancer
- csf1r inhibitors
- giant cell
- tumor
- cell tumor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G01N33/57505—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7153—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons or colony-stimulating factors [CSF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
En la presente se describen métodos para tratar cáncer y otros tumores relacionados con la disminución de la proliferación, el agotamiento o la repolarización de macrófagos asociados a tumores (TAM) y el tratamiento de trastornos asociados, incluyendo el tumor tenosinovial de células gigantes (TGCT) y el tumor tenosinovial de células gigantes de tipo difuso (DTGCT).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862786105P | 2018-12-28 | 2018-12-28 | |
| US201962926341P | 2019-10-25 | 2019-10-25 | |
| US201962933830P | 2019-11-11 | 2019-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002838A true MX2024002838A (es) | 2024-03-19 |
Family
ID=69191281
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007927A MX2021007927A (es) | 2018-12-28 | 2019-12-23 | Metodos para tratar trastornos usando inhibidores de csf1r. |
| MX2024002838A MX2024002838A (es) | 2018-12-28 | 2021-06-28 | Metodos para tratar trastornos usando inhibidores de csf1r. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007927A MX2021007927A (es) | 2018-12-28 | 2019-12-23 | Metodos para tratar trastornos usando inhibidores de csf1r. |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US11103507B2 (es) |
| EP (3) | EP4647767A3 (es) |
| JP (2) | JP7626702B2 (es) |
| KR (1) | KR20210119411A (es) |
| CN (4) | CN118453609A (es) |
| AU (2) | AU2019416117B2 (es) |
| BR (1) | BR112021012812A2 (es) |
| CA (1) | CA3124112A1 (es) |
| DK (2) | DK4303583T3 (es) |
| ES (2) | ES3049362T3 (es) |
| FI (2) | FI3902547T3 (es) |
| HR (2) | HRP20251261T1 (es) |
| HU (2) | HUE073437T2 (es) |
| IL (2) | IL284199B1 (es) |
| LT (2) | LT4303583T (es) |
| MX (2) | MX2021007927A (es) |
| PL (2) | PL3902547T3 (es) |
| PT (2) | PT4303583T (es) |
| RS (2) | RS64993B1 (es) |
| SG (1) | SG11202105747XA (es) |
| SI (2) | SI3902547T1 (es) |
| SM (2) | SMT202500389T1 (es) |
| TW (2) | TW202541807A (es) |
| WO (1) | WO2020139828A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3089630A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
| SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| HUE073437T2 (hu) * | 2018-12-28 | 2026-01-28 | Deciphera Pharmaceuticals Llc | CSF1R gátlók tenoszinoviális óriássejtes tumorok kezelésében való alkalmazásra |
| WO2020185812A1 (en) | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| EP4295846A3 (en) | 2019-05-10 | 2024-02-28 | Deciphera Pharmaceuticals, LLC | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| CN114127057B (zh) | 2019-05-10 | 2024-07-12 | 德西费拉制药有限责任公司 | 苯基氨基嘧啶酰胺自噬抑制剂及其使用方法 |
| US11590134B2 (en) | 2019-06-17 | 2023-02-28 | Deciphera Pharmaceuticals, Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| KR20220045189A (ko) | 2019-08-12 | 2022-04-12 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양을 치료하는 방법 |
| SMT202400484T1 (it) | 2019-12-30 | 2025-01-14 | Deciphera Pharmaceuticals Llc | Composizioni di 1-(4-bromo-5-(1-etil-7-(metilammino)-2-osso-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea |
| SMT202300467T1 (it) | 2019-12-30 | 2024-01-10 | Deciphera Pharmaceuticals Llc | Formulazioni di inibitori di chinasi amorfi e loro procedimenti d’uso |
| CN119454695A (zh) * | 2020-09-23 | 2025-02-18 | 上海润石医药科技有限公司 | Csf1r激酶抑制剂及其用途 |
| CA3198943A1 (en) | 2020-11-18 | 2022-05-27 | Daniel L. Flynn | Gcn2 and perk kinase inhibitors and methods of use thereof |
| CN113880812A (zh) * | 2021-11-17 | 2022-01-04 | 上海皓元生物医药科技有限公司 | 一种csf-ir抑制剂的制备方法 |
| PE20241934A1 (es) | 2021-12-09 | 2024-09-24 | Deciphera Pharmaceuticals Llc | Inhibidores de raf quinasa y metodos de uso de los mismos |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| EP4587059A2 (en) * | 2022-09-12 | 2025-07-23 | Ammax Bio, Inc | Treatment of tenosynovial giant cell tumor |
| EP4483866A1 (en) | 2023-06-28 | 2025-01-01 | Makrolife Biotech GmbH | Pharmaceutical compositions for the treatment or prevention of cancer |
| US20250205161A1 (en) | 2023-12-08 | 2025-06-26 | Deciphera Pharmaceuticals, Llc | Formulations of vimseltinib |
| TW202542127A (zh) | 2023-12-08 | 2025-11-01 | 美商迪賽孚爾製藥有限公司 | 激酶抑制劑之固態形式 |
| WO2025231106A1 (en) * | 2024-05-01 | 2025-11-06 | Deciphera Pharmaceuticals, Llc | Csf-1r inhibitors and methods of use thereof |
| CN118593504B (zh) * | 2024-06-03 | 2025-03-18 | 北京大学第三医院（北京大学第三临床医学院） | 氘可来昔替尼或其盐在制备pvns药物方面的新用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5794047A (en) | 1980-12-01 | 1982-06-11 | Ricoh Co Ltd | Novel disazo compound and preparation of the same |
| DE50213202D1 (de) | 2001-05-29 | 2009-02-26 | Bayer Schering Pharma Ag | Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel |
| KR100883731B1 (ko) | 2001-06-22 | 2009-02-12 | 기린 파마 가부시끼가이샤 | 간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물 |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| JP5197016B2 (ja) | 2004-12-23 | 2013-05-15 | デシファラ ファーマスーティカルズ， エルエルシー | 酵素モジュレータ及び治療 |
| JP5345842B2 (ja) | 2005-06-23 | 2013-11-20 | アステックス・セラピューティクス・リミテッド | プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| WO2008046216A1 (en) | 2006-10-18 | 2008-04-24 | Methylgene, Inc. | Kinase inhibitors and uses thereof |
| EP2125781A2 (en) | 2006-12-20 | 2009-12-02 | Amgen Inc. | Substituted heterocycles and methods of use |
| EP2146716A4 (en) | 2007-04-20 | 2010-08-11 | Deciphera Pharmaceuticals Llc | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYELOPROLIFERATIVE SYNDROME AND OTHER PROLIFERATIVE DISEASES |
| EP2254889B1 (en) | 2008-02-28 | 2012-12-19 | Merck Patent GmbH | Protein kinase inhibitors and use thereof |
| MX2011004535A (es) | 2008-10-29 | 2011-11-18 | Deciphera Pharmaceuticals Llc | Ciclopropanamidas y analogos que exhiben actividades anti-cancer y anti-proliferativas. |
| SG10201503394PA (en) | 2010-04-29 | 2015-06-29 | Deciphera Pharmaceuticals Llc | Cyclopropyl Dicarboxamides And Analogs Exhibiting Anti-Cancer And Anti-Proliferative Activities |
| EP2563773A1 (en) | 2010-04-29 | 2013-03-06 | Deciphera Pharmaceuticals, LLC | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
| AU2012327190B2 (en) | 2011-11-22 | 2015-12-24 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anit-cancer and anti-proliferative activities |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| US9187474B2 (en) | 2012-03-07 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Raf inhibitor compounds |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US9758258B2 (en) | 2012-11-29 | 2017-09-12 | Sirkorsky Aircraft Corporation | Rotary wing aircraft blade tracking |
| US9133183B2 (en) | 2013-03-15 | 2015-09-15 | Deciphera Pharmaceuticals, Llc | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities |
| US9012635B2 (en) | 2013-03-15 | 2015-04-21 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| WO2014145029A2 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
| KR20240013846A (ko) | 2013-03-15 | 2024-01-30 | 데시페라 파마슈티칼스, 엘엘씨. | 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체 |
| PH12015502336B1 (en) | 2013-03-15 | 2022-07-15 | Deciphera Pharmaceuticals Llc | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
| WO2014145023A1 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
| AR097584A1 (es) * | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
| EP3589324A1 (en) | 2017-03-03 | 2020-01-08 | Janssen Biotech, Inc. | Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer |
| AU2018274043C1 (en) | 2017-05-24 | 2021-08-19 | Abbisko Therapeutics Co., Ltd. | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof |
| EP3630110A1 (en) | 2017-05-30 | 2020-04-08 | Deciphera Pharmaceuticals, Inc. | Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptoralpha |
| BR112020005174A2 (pt) | 2017-09-14 | 2020-11-10 | Daiichi Sankyo Company,Limited | composto que possui estrutura cíclica |
| CA3089630A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
| HUE073437T2 (hu) * | 2018-12-28 | 2026-01-28 | Deciphera Pharmaceuticals Llc | CSF1R gátlók tenoszinoviális óriássejtes tumorok kezelésében való alkalmazásra |
| CN114127057B (zh) | 2019-05-10 | 2024-07-12 | 德西费拉制药有限责任公司 | 苯基氨基嘧啶酰胺自噬抑制剂及其使用方法 |
| EP4295846A3 (en) | 2019-05-10 | 2024-02-28 | Deciphera Pharmaceuticals, LLC | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| CA3211329A1 (en) | 2021-05-24 | 2022-12-01 | Lei Zhang | Crystalline csf-1r inhibitor acidic salt, preparation method therefor ans use thereof |
| CN113880812A (zh) | 2021-11-17 | 2022-01-04 | 上海皓元生物医药科技有限公司 | 一种csf-ir抑制剂的制备方法 |
| CN116283919A (zh) | 2023-03-21 | 2023-06-23 | 上海皓元医药股份有限公司 | Vimseltinib的新晶型及其制备方法 |
-
2019
- 2019-12-23 HU HUE23195809A patent/HUE073437T2/hu unknown
- 2019-12-23 US US16/725,282 patent/US11103507B2/en active Active
- 2019-12-23 CN CN202410608820.2A patent/CN118453609A/zh active Pending
- 2019-12-23 PT PT231958091T patent/PT4303583T/pt unknown
- 2019-12-23 PT PT198427122T patent/PT3902547T/pt unknown
- 2019-12-23 ES ES23195809T patent/ES3049362T3/es active Active
- 2019-12-23 ES ES19842712T patent/ES2964489T3/es active Active
- 2019-12-23 WO PCT/US2019/068311 patent/WO2020139828A1/en not_active Ceased
- 2019-12-23 HU HUE19842712A patent/HUE065492T2/hu unknown
- 2019-12-23 LT LTEP23195809.1T patent/LT4303583T/lt unknown
- 2019-12-23 AU AU2019416117A patent/AU2019416117B2/en active Active
- 2019-12-23 HR HRP20251261TT patent/HRP20251261T1/hr unknown
- 2019-12-23 CA CA3124112A patent/CA3124112A1/en active Pending
- 2019-12-23 FI FIEP19842712.2T patent/FI3902547T3/fi active
- 2019-12-23 JP JP2021537759A patent/JP7626702B2/ja active Active
- 2019-12-23 DK DK23195809.1T patent/DK4303583T3/da active
- 2019-12-23 SM SM20250389T patent/SMT202500389T1/it unknown
- 2019-12-23 SM SM20230468T patent/SMT202300468T1/it unknown
- 2019-12-23 EP EP25190979.2A patent/EP4647767A3/en active Pending
- 2019-12-23 PL PL19842712.2T patent/PL3902547T3/pl unknown
- 2019-12-23 SI SI201930651T patent/SI3902547T1/sl unknown
- 2019-12-23 PL PL23195809.1T patent/PL4303583T3/pl unknown
- 2019-12-23 EP EP23195809.1A patent/EP4303583B1/en active Active
- 2019-12-23 HR HRP20231478TT patent/HRP20231478T1/hr unknown
- 2019-12-23 EP EP19842712.2A patent/EP3902547B1/en active Active
- 2019-12-23 SG SG11202105747XA patent/SG11202105747XA/en unknown
- 2019-12-23 LT LTEPPCT/US2019/068311T patent/LT3902547T/lt unknown
- 2019-12-23 RS RS20231149A patent/RS64993B1/sr unknown
- 2019-12-23 CN CN202410608814.7A patent/CN118453608A/zh active Pending
- 2019-12-23 RS RS20251011A patent/RS67303B1/sr unknown
- 2019-12-23 CN CN202410608828.9A patent/CN118453610A/zh active Pending
- 2019-12-23 KR KR1020217024011A patent/KR20210119411A/ko not_active Ceased
- 2019-12-23 CN CN201980092790.1A patent/CN113453684B/zh active Active
- 2019-12-23 BR BR112021012812A patent/BR112021012812A2/pt unknown
- 2019-12-23 DK DK19842712.2T patent/DK3902547T3/da active
- 2019-12-23 MX MX2021007927A patent/MX2021007927A/es unknown
- 2019-12-23 SI SI201930977T patent/SI4303583T1/sl unknown
- 2019-12-23 FI FIEP23195809.1T patent/FI4303583T3/fi active
- 2019-12-27 TW TW114101930A patent/TW202541807A/zh unknown
- 2019-12-27 TW TW108148219A patent/TWI873113B/zh active
-
2021
- 2021-06-20 IL IL284199A patent/IL284199B1/en unknown
- 2021-06-25 US US17/358,137 patent/US11679110B2/en active Active
- 2021-06-28 MX MX2024002838A patent/MX2024002838A/es unknown
-
2023
- 2023-04-28 US US18/140,942 patent/US12285430B2/en active Active
-
2024
- 2024-07-22 AU AU2024205010A patent/AU2024205010B2/en active Active
-
2025
- 2025-01-23 JP JP2025009594A patent/JP2025066790A/ja active Pending
- 2025-03-14 US US19/079,727 patent/US12485120B2/en active Active
- 2025-12-18 IL IL325448A patent/IL325448A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024002838A (es) | Metodos para tratar trastornos usando inhibidores de csf1r. | |
| CL2020002914A1 (es) | Métodos y composiciones para tratar el cáncer | |
| CL2018003316A1 (es) | Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786) | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
| MX2019010149A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
| MX2020012261A (es) | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. | |
| MX391470B (es) | Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
| CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
| MX2019007030A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| IL285847A (en) | Methods for treating map3k8 positive cancers | |
| MX2019000200A (es) | Agentes antiproliferativos basados en pirimidina. | |
| DOP2017000035A (es) | Inhibidores de la proteina quinasa c y metodos de su uso | |
| MX2017005553A (es) | Terapia de combinacion para cancer. | |
| MX2010000465A (es) | Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores. | |
| MX2019011148A (es) | Metodos de tratamiento. | |
| MX2017013178A (es) | Terapia de combinacion para cancer. | |
| MX381582B (es) | Terapia de combinacion para el tratamiento de neoplasias malignas. | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| MX2021005400A (es) | Terapia del cancer con celulas inmunitarias anti-ptk7. | |
| MX2015000008A (es) | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. | |
| PH12022553333A1 (en) | Markers for use in methods for treating cancers with antibody drug conjugates (adc) | |
| MX2017016346A (es) | Metodos de tratamiento con taselisib. | |
| WO2019028406A3 (en) | Activation of resident memory t cells for the treatment of cancer | |
| CL2020003169A1 (es) | Métodos de uso de cd24 para prevenir y tratar la recaída de la leucemia |